

FIGURE 1





FIGURE 2



**FIGURE 3A**

**Effect of Local Compound on OHC Loss Caused by Neomycin**






FIGURE 3B



\*\*\* p<0.0001, t test


# FIGURE 3C



\*\*\* p<0.0001, † test


FIGURE 4A

Neomycin+Compound (10ng) or Neomycin+Vehicle  
Applied to Round Windows



**FIGURE 4B**

**Neomycin and Compound (1ng) or Vehicle  
Applied to Round Window**



**FIGURE 5**  
**Effect of Subcutaneous Compound**  
**on OHC Loss Caused by Neomycin**






FIGURE 6

Neomycin Applied to Round Window, Vehicle  
or Compound Administered via S.C. Injection

■ vehicle s.c. injection (n=9)  
▨ Compound s.c. injection (n=10)






FIGURE 7




**FIGURE 8**

**Neomycin and Compound (10 ng) or  
Vehicle Applied to Round Window**



\*\*\* p<0.001, t test


FIGURE 9



\*\* p<0.01, † test

FIGURE 10

Neomycin and Compound (10 ng) or Vehicle  
Applied to Round Window






Figure 11




Figure 12